A new survey from Wolters Kluwer Health reflects increasing trust in providers in non-traditional primary care settings.

FDA has approved buprenorphine extended-release injection (Brixadi—Braeburn) for the treatment of moderate to severe opioid use disorder (OUD). The drug is available as a weekly dose for patients who have started treatment with a single dose of a transmucosal buprenorphine product and as a monthly version for patients already being treated with buprenorphine.

Members of an FDA advisory panel voted in support of Pfizer’s respiratory syncytial virus (RSV) vaccine (Abrysvo) for the prevention of RSV in infants via administration to pregnant women.

Findings from a study published in NEJM suggest that a key treatment for opioid use disorder is underprescribed among patients in the United States, in particular among Black patients.

To prevent misuse, abuse, and addiction of prescription stimulants, FDA is now requiring their boxed warning—the most prominent warning—to be updated. In addition, the agency is adding more to the prescribing information for all prescription stimulants.